Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

A bevy of an­a­lysts turned out for Gilead’s Q4 call Tues­day night look­ing for some of the old siz­zle about the fu­ture that used to ex­cite them in the past. What they got was a lec­ture on steady im­prove­ment, sound judg­ment and prop­er deal­mak­ing — along with a plate­ful of slight­ly dis­ap­point­ing num­bers that left more than a few feel­ing a bit de­flat­ed by the end.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.